Biren Amin
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
42
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Initiates: Overweight | $46 | $25.48 | +80.53% | 1 | Sep 4, 2024 | |
| CRGX CARGO Therapeutics | Maintains: Overweight | $37 → $34 | $20.37 | +66.91% | 2 | Aug 13, 2024 | |
| IMNM Immunome | Maintains: Overweight | $27 → $23 | $11.59 | +98.45% | 2 | Aug 13, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $205 → $200 | $123.29 | +62.22% | 4 | Aug 8, 2024 | |
| AGEN Agenus | Downgrades: Hold | $7 → $3 | $4.05 | -25.93% | 1 | Jul 19, 2024 | |
| SLDB Solid Biosciences | Reiterates: Overweight | $20 | $5.75 | +247.83% | 1 | Jun 21, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $15 | $10.39 | +44.37% | 1 | Jun 21, 2024 | |
| ELEV Elevation Oncology | Initiates: Overweight | $10 | $0.54 | +1,765.67% | 1 | May 31, 2024 | |
| APLS Apellis Pharmaceuticals | Initiates: Neutral | $46 | $27.98 | +64.40% | 1 | May 31, 2024 | |
| ALLO Allogene Therapeutics | Initiates: Overweight | $11 | $2.72 | +304.41% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $86.17 | -18.77% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $3.32 | +2,008.43% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $2.09 | +2,340.19% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.36 | +347.76% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $1.53 | +2,122.22% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $6.99 | +7,053.08% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.33 | +50.05% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $843.60 | -18.09% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $1.05 | +852.38% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.47 | - | 4 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $21.68 | +365.87% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $122.21 | -43.54% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $471.12 | -67.10% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $2.62 | +5,090.84% | 4 | Mar 6, 2017 |
BridgeBio Pharma
Sep 4, 2024
Initiates: Overweight
Price Target: $46
Current: $25.48
Upside: +80.53%
CARGO Therapeutics
Aug 13, 2024
Maintains: Overweight
Price Target: $37 → $34
Current: $20.37
Upside: +66.91%
Immunome
Aug 13, 2024
Maintains: Overweight
Price Target: $27 → $23
Current: $11.59
Upside: +98.45%
Sarepta Therapeutics
Aug 8, 2024
Maintains: Overweight
Price Target: $205 → $200
Current: $123.29
Upside: +62.22%
Agenus
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $4.05
Upside: -25.93%
Solid Biosciences
Jun 21, 2024
Reiterates: Overweight
Price Target: $20
Current: $5.75
Upside: +247.83%
Ocular Therapeutix
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $10.39
Upside: +44.37%
Elevation Oncology
May 31, 2024
Initiates: Overweight
Price Target: $10
Current: $0.54
Upside: +1,765.67%
Apellis Pharmaceuticals
May 31, 2024
Initiates: Neutral
Price Target: $46
Current: $27.98
Upside: +64.40%
Allogene Therapeutics
May 31, 2024
Initiates: Overweight
Price Target: $11
Current: $2.72
Upside: +304.41%
May 31, 2024
Initiates: Overweight
Price Target: $70
Current: $86.17
Upside: -18.77%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $3.32
Upside: +2,008.43%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $2.09
Upside: +2,340.19%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.36
Upside: +347.76%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $1.53
Upside: +2,122.22%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $6.99
Upside: +7,053.08%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $9.33
Upside: +50.05%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $843.60
Upside: -18.09%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $1.05
Upside: +852.38%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.47
Upside: -
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $21.68
Upside: +365.87%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $122.21
Upside: -43.54%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $471.12
Upside: -67.10%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $2.62
Upside: +5,090.84%